(Q51037108)

27 March 2018

title

Gastrointestinal stromal tumour. (English)

1 reference

27 March 2018

author

Heikki Joensuu

series ordinal

1

1 reference

27 March 2018

Peter Hohenberger

series ordinal

2

object named as

Peter Hohenberger

1 reference

27 March 2018

author name string

Christopher L Corless

series ordinal

3

1 reference

27 March 2018

language of work or name

English

0 references

publication date

24 April 2013

1 reference

27 March 2018

published in

The Lancet

1 reference

27 March 2018

volume

382

1 reference

27 March 2018

page(s)

973-983

1 reference

27 March 2018

issue

9896

1 reference

27 March 2018

Histopathology of gastrointestinal stromal tumor

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumours: origin and molecular oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumor: an ultrastructural investigation on regional differences with considerations on their histogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastric stromal tumors. Reappraisal of histogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Primary leiomyosarcomas of the gastrointestinal tract in the post-gastrointestinal stromal tumor era.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

The gastric hypercellular microleiomyoma as a precursor lesion for clinical gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

High incidence of microscopic gastrointestinal stromal tumors in the stomach.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

"Seedling" mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumour.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

"Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumors: pathology and prognosis at different sites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

The risks of radiation exposure related to diagnostic imaging and how to minimise them.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Therapeutic drug monitoring of imatinib--new data strengthen the case

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Radiotherapy in the treatment of gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Management of malignant gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960106-3

7 January 2021

10.1016/S0140-6736(13)60106-3

Identifiers

DOI

1 reference

27 March 2018

PubMed ID

23623056

1 reference

27 March 2018